ArticleMaterials today. Bio2025
Dynamic DNA assembly-assisted CRISPR/Cas12a system for lung cancer-associated miRNA analysis.
Article in Materials today. Bio, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Advancements in CRISPR/Cas Technologies for Sensitive Cancer Detection: Mechanisms, Platforms, and Clinical Translation Roadmap.Diagnostics (Basel, Switzerland) · 2026Review
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- CRISPR-Cas-Based Diagnostics in Biomedicine: Principles, Applications, and Future Trajectories.Biosensors · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Serum-derived tumor-associated microRNAs (miRNAs) have emerged as clinically valuable biomarkers for early cancer detection and prognostic evaluation. The development of robust analytical platforms enabling ultrasensitive miRNA quantification remains an urgent priority in molecular diagnostics. Herein, a well-designed functional hairpin DNA template (H) combined with the CRISPR/Cas12a system was proposed as a novel strategy for ultrasensitive detection of lung cancer-associated miRNAs. The H-sequence undergoes a topological transition upon specific recognition of the target miRNA, initiating an isothermal exponential amplification reaction (iEXPAR) that continuously releases amplicons. These amplicons, in turn, activate the CRISPR/Cas12a system, resulting in signal amplification. This approach achieves a linear detection range from 20 fM to 2 nM, with an impressive detection limit as low as 26 fM. Due to the programmability of DNA sequences, this strategy holds great potential for the sensitive detection of a wide range of other nucleic acid targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.